HUDDINGE, Sweden, Oct. 10, 2023 /PRNewswire/ — XNK Therapeutics AB (“XNK”) today announced that it has applied for and been granted funding by Sweden’s innovation agency Vinnova. The grant consists of SME support through the Competence Center for Next-generation NK Cell-based Cancer…